B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 61.3%

Neg 61.3% Neu 0% Pos 0%

B. Riley Securities analyst William Woods maintains Aardvark Therapeutics (NASDAQ:AARD) with a Buy and lowers the price target from $8 to $7.